Literature DB >> 17486051

Pathology of fatty liver disease.

Elizabeth M Brunt1.   

Abstract

Fatty liver disease is currently recognized as a common cause of liver test elevation, paralleling the worldwide 'epidemic' of obesity in adults and children. In many clinical practices, there is recognition that liver biopsy evaluation is the only means of diagnosis (or exclusion) of fatty liver disease, as neither laboratory tests nor imaging studies to date can provide complete data related to amount of steatosis, inflammation, liver cell injury, fibrosis, and architectural remodeling. Liver biopsy evaluation also provides a means of 'grading and staging' the lesions of fatty liver disease and of detecting clinically unsuspected processes. Liver biopsy evaluation is often the primary end point in clinical trials of treatment, thus, standardization of diagnosis and methods of grading and staging have become important. In this review, these concepts as well as the pathophysiologic bases for them are discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17486051     DOI: 10.1038/modpathol.3800680

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  62 in total

Review 1.  Role of lipid rafts in liver health and disease.

Authors:  Angela Dolganiuc
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

Review 3.  Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin.

Authors:  Mariana Lazo; Usama Bilal; Rafael Perez-Escamilla
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

4.  The impact of diet-induced hepatic steatosis in a murine model of hepatic ischemia/reperfusion injury.

Authors:  Kim H H Liss; Kyle S McCommis; Kari T Chambers; Terri A Pietka; George G Schweitzer; Sara L Park; Ilke Nalbantoglu; Carla J Weinheimer; Angela M Hall; Brian N Finck
Journal:  Liver Transpl       Date:  2018-07       Impact factor: 5.799

5.  Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection.

Authors:  J-F Li; F Qu; S-J Zheng; H-L Wu; M Liu; S Liu; Y Ren; F Ren; Y Chen; Z-P Duan; J-L Zhang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-09       Impact factor: 3.267

Review 6.  Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment.

Authors:  Howard P Monsour; Catherine T Frenette; Kathleen Wyne
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Jul-Sep

7.  One-year chronic toxicity evaluation of single dose intravenously administered silica nanoparticles in mice and their Ex vivo human hemocompatibility.

Authors:  Raziye Mohammadpour; Darwin L Cheney; Jason W Grunberger; Mostafa Yazdimamaghani; Jolanta Jedrzkiewicz; Kyle J Isaacson; Marina A Dobrovolskaia; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2020-05-25       Impact factor: 9.776

8.  The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis.

Authors:  Daniel Ferguson; Jun Zhang; Matthew A Davis; Robert N Helsley; Lise-Lotte Vedin; Richard G Lee; Rosanne M Crooke; Mark J Graham; Daniela S Allende; Paolo Parini; J Mark Brown
Journal:  J Lipid Res       Date:  2016-12-10       Impact factor: 5.922

9.  Obesity, overweight and liver disease in the Midspan prospective cohort studies.

Authors:  C L Hart; G D Batty; D S Morrison; R J Mitchell; G Davey Smith
Journal:  Int J Obes (Lond)       Date:  2010-02-09       Impact factor: 5.095

Review 10.  Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver.

Authors:  Megan J Reiniers; Rowan F van Golen; Thomas M van Gulik; Michal Heger
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.